Joel Habener on GLP-1 Discoveries for Diabetes and Obesity Treatment

Understanding GLP-1 and its Discovery

• 💡 GLP-1 is a 31-amino-acid gluco-incretin hormone that stimulates glucose-dependent insulin secretion, making it an effective treatment for type-2 diabetes.
• 🔬 Unlike exogenous insulin shots, GLP-1 prompts the pancreas to produce its own insulin, reducing the risk of dangerously low blood sugar levels.
• 🧬 The discovery process involved cloning the glucagon gene from anglerfish, leading to the identification of glucagon-related peptide (GRP), which was later named GLP-1 in mammals.

Major Therapeutic Milestones

• ✅ GLP-1 receptor agonists have achieved significant success in treating type-2 diabetes and managing obesity, addressing related comorbidities.
• 💖 Clinical studies, like the SELECT trial, have shown a remarkable 20% reduction in heart attack and stroke risk for individuals with cardiovascular disease and obesity taking GLP-1 agonists.

Emerging Applications and Benefits

• 🧠 Beyond diabetes and obesity, GLP-1 agonists are being found effective in suppressing inflammation and show promise for neurological diseases such as Parkinson's and potentially Alzheimer's.
• 🌱 They also appear effective in treating various inflammatory disorders including inflammatory bowel disease, psoriasis, and metabolic dysfunction-associated steatohepatitis (MASH).

Responsible Use of GLP-1 Drugs

• ⚠️ The use of GLP-1 receptor agonists for cosmetic weight loss should be discussed with and approved by a physician due to potential, though generally mild, side effects.
• 🩺 It is crucial that individuals taking GLP-1 medications do so under the guidance of a physician rather than self-administering.